TSHA

Taysha Gene Therapies, Inc. (TSHA) | Rumor.io

Taysha Gene Therapies

TSHA

Attention (50-day avg)0%

Attention rank (50-day avg)#2,902

Bullish sentiment (50-day avg)100%

Price to earnings ratio2.53

Market capitalization1.6B

Earnings per share-0.41

Dividend yield (TTM)—

Revenue (annual)9.8M

Net income (annual)-109M

Social

What share of all stock conversation is about TSHA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

Jun 25

Taysha Gene Therapies, Inc. ($TSHA) has launched a 200 million dollar underwritten offering, with Goldman Sachs, Jefferies, Piper Sandler, and Cantor on the book.
The company has priced the offering at $6.00 per share, with 32.5 million new shares issued, close to a third of the company's outstanding shares.
The offering is expected to close on or about June 26, with the funds raised to be used by the company, which has no approved product and is a clinical-stage biotech.

Generated by AI

Sentiment

Of the messages about TSHA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	85.29% -9.94
Bearish	—	0%	0% 0	14.71% +9.94

Bullish· Oct 3

$TSHA's recent pullback is seen as a profit-taking and macro-driven move, with no company-specific issues.
The stock has a strong clinical data and regulatory clarity, with a consensus target of $9 and Buy ratings from 9 analysts.
$TSHA's Breakthrough Therapy Designation for its gene therapy TSHA-102 for Rett syndrome has led to a 100% response rate and a clean safety profile, with a strong cash position and no worries about dilution.

Bearish· Oct 2

$TSHA has a history of closing green on gaps above 30%, but today's price is repeating a pattern where it holds, suggesting a potential short opportunity.
The stock has a low fade score, making it a suitable candidate for a bear-bull trade, where the goal is to profit from a decline in price.
$TSHA's 60 million in debt is a concern, and a potential break below 4.35 could lead to further losses, with some traders expecting a drop to 0.35.

Generated by AI

Topics

Of the messages about TSHA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	52.9%
Earnings	—	—	—	0.59%
Analysts	—	—	—	15.21%
Controversies	—	—	—	4.92%
Macro	—	—	—	5.88%
Technical Analysis	—	—	—	20.5%

Analysts· Aug 15

Analysts at Baird raised Taysha Gene Therapies' price target to $8.
Analysts at Cantor Fitzgerald raised Taysha Gene Therapies' price target to $7, citing positive Q2 data from the REVEAL trial.
Analysts at Truist Securities maintained a Buy rating and raised the price target to $6, while Needham lowered its target to $5.

Announcements· Oct 2

$TSHA has been granted FDA Breakthrough Therapy designation for TSHA-102, an AAV9 gene therapy for Rett syndrome.
The company has finalized alignment with the FDA on the REVEAL pivotal trial protocol and statistical analysis plan for the planned Biologics License Application.
The REVEAL Phase 1/2 trials showed a 100% response rate in Part A for developmental milestone achievement, with the treatment deepening over time.

Technical Analysis· Oct 2

$TSHA has a history of closing green on gaps above 30% by 100% on 4 gaps, and is repeating the same pattern today.
The stock is holding up well as the broad market looks weak, and a break above 4.50 could lead to a potential move to 4.70/4.80.
A double top formation is possible, and if 4.35 breaks, the stock may decline, but if it maintains its surge, potential targets may be around $4.90, $5.05, and $5.45.

Generated by AI

Community

Of the messages about TSHA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	60%	36.36%	26.04%
Newcomers	—	40%	63.64%	73.96%

Regulars· Oct 2

$TSHA has been granted Breakthrough Therapy designation by the FDA for its AAV9 gene therapy for Rett syndrome, TSHA-102, and has finalized alignment with the FDA on the REVEAL pivotal trial protocol and statistical analysis plan.
Regulars are optimistic about the company's potential, with some citing a TAM (total addressable market) of $5-8 billion globally for disease-modifying therapies.
Baird analyst Jack Allen has raised the firm's price target on $TSHA to $12 from $7, citing the company's progress in reaching alignment with the FDA on the pivotal study of TSHA-102.

Newcomers· Oct 17

Newcomers are focusing on the comparison between Taysha Gene Therapies ($TSHA) and Sangamo ($SGMO) in terms of market capitalization, with $TSHA having a significantly larger market cap.
The discussion among newcomers centers around the potential implications of Astellas' decision to drop $TSHA, including the possibility of $TSHA regaining its rights to a key asset.
Newcomers are also noting the market performance of $TSHA, with the stock price experiencing a decline, and are referencing recent news articles and updates about Taysha Gene Therapies' progress in treating Rett syndrome.

Generated by AI

News

Wolfe Research Initiates Taysha Gene Therapies at Outperform

Taysha Gene Therapies (TSHA) has an average rating of buy and mean price target of $13, according to

13d agoYahoo Finance

Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval

18d agoSeeking Alpha

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on September 1, 2026, the Compensation Committee of Taysha's Board of Directors granted five new employees restricted stock units (RSUs) representing 314,000 shares of the Company’s common s

26d agoYahoo! Finance Canada

Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call

Detailed price information for Taysha Gene Therapies Inc (TSHA-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Wall Street Analysts Are Bullish on Top Healthcare Picks

Detailed price information for Spyre Therapeutics Inc (SYRE-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger

Taysha Gene Therapies (TSHA) drew fresh investor attention after reporting a 100% overall response rate in early TSHA-102 Rett syndrome trial data, expanding its Catalent manufacturing agreement, and outlining cash coverage into late 2028. See our latest analysis for Taysha Gene Therapies. Taysha Gene Therapies has seen its share price move around these updates, with a 19.05% 30 day share price return and a very large 1 year total shareholder return, while the 5 year total shareholder return...

1mo agoYahoo Finance

Also Discussed

Investors talking about TSHA also mention

#	Name	Attention
1	Neurogene Inc.NGNE	0%0
2	Tango Therapeutics Inc.TNGX	0%new
3	Acumen Pharmaceuticals, Inc.ABOS	0%new
4	PaxMedica Inc.PXMD	0%0
5	Nkarta, Inc.NKTX	0%0
6	MF - Missfresh Limited	——
7	Edgewise Therapeutics Inc.EWTX	0%new
8	LVTX - LAVA Therapeutics N.V.	——
9	Sensus Healthcare Inc.SRTS	0%0
10	Sutro Biopharma Inc.STRO	0%new

Taysha Gene Therapies, Inc.

Healthcare
Biotechnology

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Taysha Gene Therapies works on treatments designed to address the genetic root causes of rare neurological disorders, with a pipeline that includes programs for Rett syndrome, giant axonal neuropathy, CLN1 disease, CLN7 disease, SLC13A5 deficiency, fragile X syndrome, angelman syndrome, and tauopathies. The company’s current work centers on advancing its lead clinical programs and translating AAV gene therapy platforms into potential disease-modifying medicines for underserved patient populations. Based in Dallas, Texas, Taysha Gene Therapies operates within the broader biotechnology sector, where it contributes to the development of specialized therapies for rare central nervous system disorders.

Website

Location

3000 Pegasus Park Drive

Dallas, TX, 75247

United States

Social

What share of all stock conversation is about TSHA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

Jun 25

Taysha Gene Therapies, Inc. ($TSHA) has launched a 200 million dollar underwritten offering, with Goldman Sachs, Jefferies, Piper Sandler, and Cantor on the book.
The company has priced the offering at $6.00 per share, with 32.5 million new shares issued, close to a third of the company's outstanding shares.
The offering is expected to close on or about June 26, with the funds raised to be used by the company, which has no approved product and is a clinical-stage biotech.

Generated by AI

Sentiment

Of the messages about TSHA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	85.29% -9.94
Bearish	—	0%	0% 0	14.71% +9.94

Bullish· Oct 3

$TSHA's recent pullback is seen as a profit-taking and macro-driven move, with no company-specific issues.
The stock has a strong clinical data and regulatory clarity, with a consensus target of $9 and Buy ratings from 9 analysts.
$TSHA's Breakthrough Therapy Designation for its gene therapy TSHA-102 for Rett syndrome has led to a 100% response rate and a clean safety profile, with a strong cash position and no worries about dilution.

Bearish· Oct 2

$TSHA has a history of closing green on gaps above 30%, but today's price is repeating a pattern where it holds, suggesting a potential short opportunity.
The stock has a low fade score, making it a suitable candidate for a bear-bull trade, where the goal is to profit from a decline in price.
$TSHA's 60 million in debt is a concern, and a potential break below 4.35 could lead to further losses, with some traders expecting a drop to 0.35.

Generated by AI

Topics

Of the messages about TSHA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	52.9%
Earnings	—	—	—	0.59%
Analysts	—	—	—	15.21%
Controversies	—	—	—	4.92%
Macro	—	—	—	5.88%
Technical Analysis	—	—	—	20.5%

Analysts· Aug 15

Analysts at Baird raised Taysha Gene Therapies' price target to $8.
Analysts at Cantor Fitzgerald raised Taysha Gene Therapies' price target to $7, citing positive Q2 data from the REVEAL trial.
Analysts at Truist Securities maintained a Buy rating and raised the price target to $6, while Needham lowered its target to $5.

Announcements· Oct 2

$TSHA has been granted FDA Breakthrough Therapy designation for TSHA-102, an AAV9 gene therapy for Rett syndrome.
The company has finalized alignment with the FDA on the REVEAL pivotal trial protocol and statistical analysis plan for the planned Biologics License Application.
The REVEAL Phase 1/2 trials showed a 100% response rate in Part A for developmental milestone achievement, with the treatment deepening over time.

Technical Analysis· Oct 2

$TSHA has a history of closing green on gaps above 30% by 100% on 4 gaps, and is repeating the same pattern today.
The stock is holding up well as the broad market looks weak, and a break above 4.50 could lead to a potential move to 4.70/4.80.
A double top formation is possible, and if 4.35 breaks, the stock may decline, but if it maintains its surge, potential targets may be around $4.90, $5.05, and $5.45.

Generated by AI

Community

Of the messages about TSHA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	60%	36.36%	26.04%
Newcomers	—	40%	63.64%	73.96%

Regulars· Oct 2

$TSHA has been granted Breakthrough Therapy designation by the FDA for its AAV9 gene therapy for Rett syndrome, TSHA-102, and has finalized alignment with the FDA on the REVEAL pivotal trial protocol and statistical analysis plan.
Regulars are optimistic about the company's potential, with some citing a TAM (total addressable market) of $5-8 billion globally for disease-modifying therapies.
Baird analyst Jack Allen has raised the firm's price target on $TSHA to $12 from $7, citing the company's progress in reaching alignment with the FDA on the pivotal study of TSHA-102.

Newcomers· Oct 17

Newcomers are focusing on the comparison between Taysha Gene Therapies ($TSHA) and Sangamo ($SGMO) in terms of market capitalization, with $TSHA having a significantly larger market cap.
The discussion among newcomers centers around the potential implications of Astellas' decision to drop $TSHA, including the possibility of $TSHA regaining its rights to a key asset.
Newcomers are also noting the market performance of $TSHA, with the stock price experiencing a decline, and are referencing recent news articles and updates about Taysha Gene Therapies' progress in treating Rett syndrome.

Generated by AI

Taysha Gene Therapies

Social

Jun 25

Bullish· Oct 3

Bearish· Oct 2

Analysts· Aug 15

Announcements· Oct 2

Technical Analysis· Oct 2

Regulars· Oct 2

Newcomers· Oct 17

Wolfe Research Initiates Taysha Gene Therapies at Outperform

Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call

Wall Street Analysts Are Bullish on Top Healthcare Picks

Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger

Also Discussed

Taysha Gene Therapies, Inc.

Company Information

Location

Wolfe Research Initiates Taysha Gene Therapies at Outperform

Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call

Wall Street Analysts Are Bullish on Top Healthcare Picks

Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger

Also Discussed

Social

Jun 25

Bullish· Oct 3

Bearish· Oct 2

Analysts· Aug 15

Announcements· Oct 2

Technical Analysis· Oct 2

Regulars· Oct 2

Newcomers· Oct 17